Lukas Käsmann - Concepedia

Author

Lukas Käsmann

Ludwig-Maximilians-Universität München ORCID

Also Known As

Käsmann, Lukas, L Ksmann, L. Käsmann, L.T. Käsmann, LUKAS KÄSMANN, Lukas Käsmann, Lukas Ksmann, Lukas Käsmann, Young DEGRO Trial Group

198

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München LMU Klinikum Deutschen Konsortium für Translationale Krebsforschung University of Lübeck German Center for Lung Research

About

Lukas Käsmann is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	172
2	Health Sciences	3	3	47
3	Immunology	3	3	107
4	Pathology	2	2	88
5	Otolaryngology	1	1	10

Lukas Käsmann

Publications

705

Citations

H-Index

Page 1

	Year	Citations
Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy Jing Sun, Run Shi, Xiaowen Zhang, OncoImmunology Tumor ImmunologyCancer ImmunosurveillanceMedicinePapillary Thyroid CancerImmunology	2021	46
Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition Qiqi Liu, Yuying Hao, Rui Du, Translational Lung Cancer Research	2021	43
Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer Lukas Käsmann, Louisa Bolm, Steven E. Schild, Lung Cancer ImmunosurveillanceMedicineImmunologyPathologyBronchial Neoplasm	2017	42
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients Julian Taugner, Lukas Käsmann, Chukwuka Eze, Investigational New Drugs	2021	41
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy K. Gennen, Lukas Käsmann, Julian Taugner, Radiation Oncology	2020	40
Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report Sanziana Schiopu, Lukas Käsmann, Ulf Schönermarck, Translational Lung Cancer Research	2021	27
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting Julian Taugner, Lukas Käsmann, Chukwuka Eze, Cancers	2021	26
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment Lukas Käsmann, Julian Taugner, Chukwuka Eze, Anticancer Research	2019	25
Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer Julian Taugner, Chukwuka Eze, Lukas Käsmann, Radiation Oncology	2020	25
State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey Lukas Käsmann, Chukwuka Eze, M. Dantes, European Journal of Cancer Radiation MedicineRadiation TherapyMedicineImmune Checkpoint InhibitorClinical Radiation Oncology	2019	22

Page 1